title: Quantification of fibrin degradation products in glioma and meningioma patients.
abstract: BACKGROUND
  DR-70 is an immunoassay for fibrin and FDP in plasma and it has been shown useful in detection of over 14 different cancers. This study investigated the validity of the DR-70 test in gliomas as well as meningiomas.
  
  
  METHODS
  77 brain tumor patients as well as 40 healthy individuals were prospectively included in the study and investigated using DR-70 kit. The glioma cohort of 33 patients consisted of 1, 11, 6 and 15 WHO grade 1, 2, 3 and 4 gliomas, respectively. The meningioma cohort of 44 patients contained 38, 5 and 1 WHO grade 1, 2 and 3 tumors.
  
  
  RESULTS
  Test results were significantly higher than control values for both gliomas and meningiomas. The most balanced sensitivity and specificity values were obtained at cut-off level of 0.5 μg/ml FDP for both gliomas and meningiomas. Above this cutoff level the relative-risk for having a glioma was 5.1 times higher compared to controls with sensitivity and specificity of 76% and 85%, respectively. The relative-risk for meningioma was 5.8 with a sensitivity and specificity of 87% and 85%, respectively.
  
  
  CONCLUSIONS
  FDP testing, which is a nonspecific cancer screening tool, is sensitive to the two most common primary brain malignancies, gliomas and meningiomas.
authors.affiliation: Department of Medical Biochemistry, Acibadem Univeristy, Istanbul, Turkey Acibadem University Neuroscience Center - Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
authors.forename: Ozge
authors.initials: O
authors.lastname: Can
authors.affiliation: Department of Medical Biochemistry, Acibadem Univeristy, Istanbul, Turkey Acibadem University Neuroscience Center - Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
authors.forename: Yigit
authors.initials: Y
authors.lastname: Erdemgil
authors.affiliation: Department of Medical Biochemistry, Acibadem Univeristy, Istanbul, Turkey Acibadem University Neuroscience Center - Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
authors.forename: Zeynep Zulfiye
authors.initials: ZZ
authors.lastname: Yildirim
authors.affiliation: Department of Neurosurgery, Acibadem Univeristy, Istanbul, Turkey Acibadem University Neuroscience Center - Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
authors.forename: Koray
authors.initials: K
authors.lastname: Ozduman
authors.affiliation: Department of Neurosurgery, Acibadem Univeristy, Istanbul, Turkey Acibadem University Neuroscience Center - Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
authors.forename: M Necmettin
authors.initials: MN
authors.lastname: Pamir
authors.affiliation: Department of Pathology, School of Medicine, Acibadem University, Istanbul, Turkey Acibadem University Neuroscience Center - Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
authors.forename: Aydin
authors.initials: A
authors.lastname: Sav
authors.affiliation: Department of Medical Biochemistry, Acibadem Univeristy, Istanbul, Turkey Acibadem University Neuroscience Center - Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
authors.forename: Aysel
authors.initials: A
authors.lastname: Ozpinar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000097:blood* / Q000473:pathology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D005910:Glioma / Q000097:blood* / Q000473:pathology; D006801:Humans; D008297:Male; D008579:Meningioma / Q000097:blood* / Q000473:pathology; D008875:Middle Aged
chemical_list: D005338:Fibrin Fibrinogen Degradation Products
keywords: DR-70; Meningioma; fibrin degradation products; glioma